Table 2.

Active analogue type and dose at baseline and 12 months.

Active analogue	Baseline (µmcg) mean ± s.d. (n)	12 month (µmcg) mean ± s.d. (n)	Wilcoxon signed-rank test (P)
1-Alfacalcidol	0.76 ± 1.30 (n = 40)	0.58 ± 0.95 (n = 37)	0.103
Paricalcitol	8.00 (n = 1)	8.00 (n = 1)	N/A
Calcitriol	0.92 ± 0.95 (n = 3)	0.79 ± 1.05 (n = 3)	0.180
Total combined	0.94 ± 1.64 (n = 44)	0.77 ± 1.43 (n = 41)	0.73

Forty-four of 55 (80%) subjects were prescribed an active analogue at the start of the study. 1-Alfacalcidol accounted for 91% of active analogue prescriptions (40 of 44), three patients were prescribed calcitriol and only one patient was prescribed paricalcitol. There was no significant change in active analogue use during the 12-month study period, n  = 55.